ArticleACS medicinal chemistry letters2025
SSTR-Mediated Precision Delivery: Overcoming Triptolide's Limitations through Octreotide Conjugation in Pancreatic Cancer Treatment.
Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Octreotide-Mediated Co-Solubilization of Paclitaxel and Docetaxel: A Novel Targeted Formulation for Synergistic Anticancer Chemotherapy.Pharmaceutics · 2026Article
- Triptolide: A Narrative Review of Its Traditional Use, Derivatives, Pharmacology, Antitumor Effect, and Clinical Applications.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer, a highly aggressive malignancy, primarily relies on chemotherapy, with existing drugs showing limited efficacy and selectivity. Triptolide (TPL), a broad-spectrum anticancer agent, exhibits potent antitumor activity but suffers from high toxicity, poor selectivity, and low water solubility. To address these limitations, we constructed the targeted prodrug TPL-OCT by conjugating TPL with octreotide (OCT), a somatostatin receptor (SSTR)-specific ligand highly expressed in pancreatic cancer cells, using succinic anhydride as a linker. This novel strategy simultaneously enhanced TPL's physicochemical properties (particularly aqueous solubility) through chemical modification and achieved tumor-targeted delivery via SSTR-mediated specificity. The optimized prodrug demonstrates improved therapeutic safety and efficacy, offering a promising approach for pancreatic cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.